The HER2- and heregulin b1 (HRG)-inducible TNFR superfamily member Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression

Molecular Cancer Research

Volumn 11, Issue 4, 2013, Pages 393-404

  Asrani, Kaushal ^a   Keri, Ruth A ^b   Galisteo, Rebeca ^a   Brown, Sharron A N ^a   Morgan, Sarah J ^a   Ghosh, Arundhati ^a   Tran, Nhan L ^c   Winkles, Jeffrey A ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR INDUCIBLE 14; GELATINASE B; HEREGULIN BETA1; LAPATINIB; MESSENGER RNA; NEU DIFFERENTIATION FACTOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; TUMOR NECROSIS FACTOR RECEPTOR; TWEAK RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL CELL; BREAST CANCER; CANCER INVASION; CELL MIGRATION; CONTROLLED STUDY; METASTASIS; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RNA INTERFERENCE; STABLE TRANSFECTION; ANIMAL; BIOSYNTHESIS; BREAST TUMOR; CELL MOTION; DISEASE MODEL; FEMALE; GENETIC TRANSFECTION; GENETICS; HUMAN; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

MUS MUSCULUS;

ANIMALS; BREAST NEOPLASMS; CELL MOVEMENT; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, TRANSGENIC; NEUREGULIN-1; RECEPTOR, ERBB-2; RECEPTORS, TUMOR NECROSIS FACTOR; TRANSFECTION;

EID: 84876531010     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-12-0542     Document Type: Article

References (50)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007;26:6469-87. (Pubitemid 47530601)
3. Campbell MR, Amin D, Moasser MM. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res 2010;16:1373-83.
4. Naidu R, Yadav M, Nair S, Kutty MK. Expression of c-erbB3 protein in primary breast carcinomas. Br J Cancer 1998;78:1385-90. (Pubitemid 28495255)
5. Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 2003;284:54-65. (Pubitemid 36342255)
6. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008;68: 5878-87.
7. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007;445:437-41. (Pubitemid 46160912)
8. Montero JC, Rodríguez-Barrueco R, Ocana A, Díaz- Rodríguez E, Esparís-Ogando A, Pandiella A. Neuregulins and cancer. Clin Cancer Res 2008;14:3237-41.
9. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002;2:127-37. (Pubitemid 41039113)
10. Xue C, Liang F, Mahmood R, Vuolo M, Wyckoff J, Qian H, et al. ErbB3-dependent motility and intravasation in breast cancer metastasis. Cancer Res 2006;66:1418-26. (Pubitemid 43259922)
11. Hernandez L, Smirnova T, Kedrin D, Wyckoff J, Zhu L, Stanley ER, et al. The EGF/CSF-1 paracrine invasion loop can be triggered by heregulin beta1 and CXCL12. Cancer Res 2009;69:3221-7.
12. Kushima Y, Iida K, Nagaoka Y, Kawaratani Y, Shirahama T, Sakaguch M, et al. Inhibitory effect of (-)-epigallocatechin and (-)-epigalloca-techin gallate against heregulin beta1-induced migration/invasion of the MCF-7 breast carcinoma cell line. Biol Pharm Bull 2009;32: 899-904.
13. Atlas E, Cardillo M, Mehmi I, Zahedkargaran H, Tang C, Lupu R. Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo. Mol Cancer Res 2003; 1:165-75. (Pubitemid 36330198)
14. Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 2011;147:992-1009.
15. Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J, Kumar R. Heregulin regulates cytoskeletal reorganization and cel migration through the p21-activated kinase-1 via phosphatidylinosi-tol-3 kinase. J Biol Chem 1998;273:28238-46. (Pubitemid 28496122)
16. Benlimame N, He Q, Jie S, Xiao D, Xu YJ, Loignon M, et al. FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion. J Cell Biol 2005;171:505-16. (Pubitemid 41586939)
17. Yao J, Xiong S, Klos K, Nguyen N, Grijalva R, Li P, et al. Multiple signaling pathways involved in activation of matrix metalloproteinase-9(MMP-9) byheregulin-beta1 in human breast cancer cells. Oncogene 2001;20:8066-74. (Pubitemid 34028331)
18. Kessenbrock K, Plaks V, Werb Z. Matrixmetalloproteinases: regulators of the tumor microenvironment. Cell 2010;141:52-67.
19. Bosc DG, Goueli BS, Janknecht R. HER2/Neu-mediated activation of the ETS transcription factor ER81 and its target gene MMP-1. Oncogene 2001;20:6215-24. (Pubitemid 32964434)
20. Yuan G, Qian L, Song L, Shi M, Li D, Yu M, et al. Heregulin-beta promotes matrix metalloproteinase-7 expression via HER2-mediated AP-1 activation in MCF-7 cells. Mol Cell Biochem 2008;318:73-9.
21. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008;7: 411-25. (Pubitemid 351619113)
22. Burkly LC, Michaelson JS, Zheng TS. TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses. Immunol Rev 2011;244:99-114.
23. Kwon OH, Park SJ, Kang TW, Kim M, Kim JH, Noh SM, et al. Elevated fibroblast growth factor-inducible 14 expression promotes gastric cancergrowth via nuclear factor-kB and is associated with poor patient outcome. Cancer Lett 2012;314:73-81.
24. Tran NL, McDonough WS, Savitch BA, Sawyer TF, Winkles JA, Berens ME. The tumor necrosis factor-like weak inducer of apo-ptosis (TWEAK)-fibroblast growth factor-inducible 14(Fn14) signaling system regulates glioma cell survival via NF-kappaB pathway activation and BCL-XL/BCL-W expression. J Biol Chem 2005;280: 3483-92. (Pubitemid 40223813)
25. Tran NL, McDonough WS, Savitch BA, Fortin SP, Winkles JA, Symons M, et al. Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-kappaB and correlate with poor patient outcome. Cancer Res 2006;66:9535-42. (Pubitemid 44623652)
26. Willis AL, Tran NL, Chatigny JM, Charlton N, Vu H, Brown SAN, et al. The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity. Mol Cancer Res 2008;6:725-34.
27. Whitsett TG, Cheng E, Inge L, Asrani K, Nathan M, Hostetter G, et al. Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion. Am J Pathol 2012;181:111-20.
28. Huang M, Narita S, Tsuchiya N, Ma Z, Numakura K, Obara T, et al. Overexpression of Fn14 promotes androgen-independent prostate cancer progression through MMP-9 and correlates with poor treatment outcome. Carcinogenesis 2011;32:1589-96.
29. Ho DH, Vu H, Brown SAN, Donohue PJ, Hanscom HN, Winkles JA. Soluble tumor necrosis factor-like weak inducer of apoptosis overexpression in HEK293 cells promotes tumor growth and angiogenesis in athymic nude mice. Cancer Res 2004;64: 8968-72. (Pubitemid 39665505)
30. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 1992;89:10578-82.
31. Landis MD, Seachrist DD, Monta~nez-Wiscovich ME, Danielpour D, Keri RA. Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice. Oncogene 2005; 24:5173-90. (Pubitemid 41192434)
32. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992;12:954-61.
33. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 2003;163:2113-26. (Pubitemid 37310040)
34. Jelovac D, Sabnis G, Long BJ, Macedo L, Goloubeva OG, Brodie AMH. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. Cancer Res 2005;65:5380-9. (Pubitemid 40834290)
35. Brown SAN, Ghosh A, Winkles JA. Full-length, membrane-anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF-kappaB pathway. J Biol Chem 2010;285: 17432-41.
36. Yepes M, Brown SAN, Moore EG, Smith EP, Lawrence DA, Winkles JA. A soluble Fn14-Fc decoy receptor reduces infarct volume in a murine model of cerebral ischemia. Am J Pathol 2005;166: 511-20. (Pubitemid 40189047)
37. Brown SAN, Richards CM, Hanscom HN, Feng SL, Winkles JA. The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-kB activation. Biochem J 2003;371:395-403. (Pubitemid 36547622)
38. Michaelson JS, Cho S, Browning B, Zheng TS, Lincecum JM, Wang MZ, et al. TWEAK induces mammary epithelial branching morphogenesis. Oncogene 2005;24:2613-24. (Pubitemid 40593089)
39. Chao DT, Su M, Tanlimco S, Sho M, Choi D, Fox M, et al. Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb. J Cancer Res Clin Oncol 2013;139: 315-25.
40. Siegel PM, Ryan ED, Cardiff RD, Muller WJ. Elevated expression of activatedformsofNeu/ErbB-2 andErbB-3are involvedinthe induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J 1999;18:2149-64. (Pubitemid 29179172)
41. Moy B, Kirkpatrick P, Kar S, Goss P. Lapatinib. Nat Rev Drug Discov 2007;6:431-2. (Pubitemid 47064564)
42. Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W, Ullrich A. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J 1995;14:4267-75.
43. Lin CW, Shen SC, Hou WC, Yang LY, Chen YC. Heme oxygenase-1 inhibits breast cancer invasion via suppressing the expression of matrix metalloproteinase-9. Mol Cancer Ther 2008;7:1195-206.
44. Niu G, Carter WB. Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways. Cancer Res 2007;67: 1487-93. (Pubitemid 46383372)
45. Merkhofer EC, Cogswell P, Baldwin AS. Her2 activates NF-kappaB and induces invasion through the canonical pathway involving IKKal-pha. Oncogene 2010;29:1238-48.
46. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-27. (Pubitemid 44854747)
47. Mitra D, Brumlik MJ, Okamgba SU, Zhu Y, Duplessis TT, Parvani JG, et al. An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Mol Cancer Ther 2009;8:2152-62.
48. Winkles JA, Tran NL, Berens ME. TWEAK and Fn14: new molecular targets for cancer therapy? Cancer Lett 2006;235:11-7.
49. Pohlmann PR, Mayer IA, Mernaugh R. Resistance to trastuzumab in breast cancer. Clin Cancer Res 2009;15:7479-91.
50. Chen FL, Xia W, Spector NL. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors. Clin Cancer Res 2008;14:6730-4.